MO — Altria Group, Inc.

Market tone is neutral-to-cautious. The late-August 2026 dividend hike to $1.11 per quarter and the PMI manufacturing agreement are supportive, and Q2 2026 adjusted EPS of $1.48 was close to the $1.49 consensus. But analyst consensus is mixed and the average price target near $70-$71 implies almost no upside from the 2026-09-13 price of $68.98. The 1-month +7.15% bounce has been offset by a 3-month -4.11% decline, so flows look income-driven rather than growth-driven.

Revenue inflected higher in 2026: Q1 2026 revenue of $5.428B was +20.1% YoY, and Q2 2026 revenue of $6.111B was +15.5% YoY, after a flat-to-down 2024-2025 stretch (Q4 2025 -0.5% YoY, Q3 2025 -1.7% YoY). However, margins compressed: Q2 2026 operating margin was 51.3% versus 61.1% in Q2 2025, and net income fell 3.4% YoY to $2.298B despite the revenue jump. EPS is volatile due to one-offs (Q1 2025 $0.63, Q4 2025 $0.66, Q2 2024 $2.21), but adjusted EPS is steadier: Q2 2026 adjusted EPS was $1.48, and FY26 guidance is $5.61-$5.72. The core smokeable margin remains strong at roughly 64.9%, and on! PLUS is scaling, but the long-term trend is still pricing power offsetting secular cigarette volume decline, not organic volume growth.

As of 2026-09-13, MO trades at 14.55x TTM EPS of $4.769 and about 12.1x next-FY EPS of $5.679, below its 5-year average P/E of 16.09. The 6.09% trailing dividend yield, or roughly 6.4% forward after the August hike, is the key valuation support. Price/sales is 5.27x versus a 5-year average of 4.16x, so the earnings multiple looks cheaper while the sales multiple looks richer. PEG is negative because earnings have been uneven, and P/B is not meaningful given negative equity. Net: roughly fair, with a modest income-driven discount on earnings.

The 2026-09-13 price of $68.98 embeds about 12.1x forward EPS of $5.679 and a 6.4% forward dividend yield; it is not pricing in much growth. If FY26 adjusted EPS lands at the $5.61-$5.72 guidance midpoint (~$5.665), the multiple is ~12.2x. A re-rating to the 5-year average P/E of 16x would imply about $90, but that seems unrealistic given volume declines and regulation. More likely, the stock trades on yield and defense; a miss on volume or on! share gains could compress the multiple toward 11x (~$62), while margin resilience and steady capital returns could support 13x (~$74).

As of 2026-09-13, RSI(14) was 52.52, neutral. Price was 1.76% above the 20-day SMA, 0.72% below the 50-day SMA, and 3.6% above the 200-day SMA, inside a 52-week range of $54.70-$77.06. After a +7.15% one-month bounce but a -4.11% three-month decline, the stock is range-bound with a mild upward bias. Entry-timing implication: there is no oversold signal, so waiting for a pullback toward the 50-day or 200-day SMA would offer better risk/reward; the dividend supports holding through weakness.

• Elevated Treasury yields and fixed-income competition create a higher hurdle rate for high-dividend defensives like Altria.
• U.S. tobacco regulation remains the dominant sector risk, including potential menthol bans, nicotine caps, and FDA product standards.
• Secular cigarette volume decline continues as U.S. adult smoking rates sit below 15%, forcing Altria to offset volume with price increases.
• Next-generation nicotine competition is intensifying, especially PMI's Zyn versus Altria's on! and on! PLUS oral pouches.
• Consumer staples rotation can provide defensive inflows during macro risk-off periods, but the sector's growth profile remains low.

• Q3 2026 earnings release expected October 29, 2026, with consensus EPS around $1.51; investors will focus on smokeable volume erosion and on! pouch share gains.
• National scale-up of on! PLUS across roughly 120,000 stores and whether it can slow share loss to Zyn in oral nicotine.
• Cost and operational benefits from the August 24, 2026 PMI manufacturing agreement.
• Further capital returns after the late-August 2026 dividend hike, including potential buyback capacity.
• FDA or legislative decisions on menthol, nicotine caps, or other tobacco regulatory actions.

• Accelerating U.S. cigarette volume declines that pricing power cannot fully offset.
• Regulatory crackdowns, including menthol bans, nicotine limits, or punitive taxation.
• Competitive pressure from PMI's Zyn and other smoke-free nicotine products threatening Altria's next-gen transition.
• Balance sheet strain: negative stockholders' equity, long-term debt of $22.893B at 2026-06-30, and a current ratio of 0.441.
• Dividend coverage risk if free cash flow weakens; Q2 2026 free cash flow was -$147M, though TTM FCF remains around $8.3B.

Altria is a high-margin, high-dividend cash cow with a 6.4% forward yield and strong ROIC of 34.3%, but it faces structural U.S. cigarette volume decline, regulatory threats, and stiff next-gen competition from Zyn. At about 12x forward EPS, the stock is not expensive, but the deterministic score's Poor Fundamentals band and Neutral valuation context map to a Bearish lean. I would not chase it for total return; the income case is intact, but capital appreciation is likely capped unless on! or regulatory outcomes surprise positively.

I apply a 13.0x forward P/E to next-FY consensus EPS of $5.679, yielding $73.83. This multiple sits between the current ~12.1x forward P/E and the 5-year average TTM P/E of 16.09x, reflecting Altria's high dividend yield and strong cash generation offset by low growth and regulatory risk.